Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. more
Time Frame | SHPH | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.46% | -2.27% | -0.57% |
1-Month Return | -38.32% | -3.96% | 1.21% |
3-Month Return | -59.72% | -9.7% | 7.57% |
6-Month Return | -80.5% | -3.37% | 11.45% |
1-Year Return | -81.75% | 3.71% | 28.48% |
3-Year Return | -99.78% | 3.8% | 29.52% |
Dec '18 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 54.95K | 60.83K | 66.83K | 6.81K | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":82.22,"profit":true},{"date":"2021-12-31","value":91.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":10.19,"profit":true}] |
Gross Profit | - | (54.95K) | (60.83K) | (66.83K) | (6.81K) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5495100,"profit":false},{"date":"2021-12-31","value":-6083400,"profit":false},{"date":"2022-12-31","value":-6683200,"profit":false},{"date":"2023-12-31","value":-681100,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | - | 509.52K | 1.74M | 2.55M | 5.89M | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":8.66,"profit":true},{"date":"2021-12-31","value":29.61,"profit":true},{"date":"2022-12-31","value":43.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | - | (509.52K) | (1.74M) | (2.55M) | (5.89M) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-50952200,"profit":false},{"date":"2021-12-31","value":-174299200,"profit":false},{"date":"2022-12-31","value":-255427800,"profit":false},{"date":"2023-12-31","value":-589238000,"profit":false}] |
Total Non-Operating Income/Expense | - | (335.84K) | 540.07K | (1.44M) | (2.72M) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-62.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-267.38,"profit":false},{"date":"2023-12-31","value":-503.08,"profit":false}] |
Pre-Tax Income | - | (805.73K) | (1.15M) | (3.03M) | (6.59M) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-80573200,"profit":false},{"date":"2021-12-31","value":-115213400,"profit":false},{"date":"2022-12-31","value":-302844800,"profit":false},{"date":"2023-12-31","value":-659272300,"profit":false}] |
Income Taxes | - | 39.63K | 50.79K | 71.01K | (1.00) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":55.81,"profit":true},{"date":"2021-12-31","value":71.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (845.36K) | (1.20M) | (3.10M) | (6.59M) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-84536200,"profit":false},{"date":"2021-12-31","value":-120292200,"profit":false},{"date":"2022-12-31","value":-309945700,"profit":false},{"date":"2023-12-31","value":-659272200,"profit":false}] |
Income From Continuous Operations | - | (805.73K) | (1.15M) | (3.03M) | (5.70M) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-80573200,"profit":false},{"date":"2021-12-31","value":-115213400,"profit":false},{"date":"2022-12-31","value":-302844800,"profit":false},{"date":"2023-12-31","value":-570313200,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | - | (845.36K) | (1.20M) | (3.10M) | (6.59M) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-84536200,"profit":false},{"date":"2021-12-31","value":-120292200,"profit":false},{"date":"2022-12-31","value":-309945700,"profit":false},{"date":"2023-12-31","value":-659272300,"profit":false}] |
EPS (Diluted) | - | - | - | (0.14) | (3.52) | [{"date":"2018-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-14,"profit":false},{"date":"2023-12-31","value":-352.5,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SHPH | |
---|---|
Cash Ratio | 0.09 |
Current Ratio | 0.22 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SHPH | |
---|---|
ROA (LTM) | -61.69% |
ROE (LTM) | -186.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SHPH | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.95 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SHPH | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.16 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Shuttle Pharmaceuticals Inc (SHPH) share price today is $0.6847
Yes, Indians can buy shares of Shuttle Pharmaceuticals Inc (SHPH) on Vested. To buy Shuttle Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SHPH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Shuttle Pharmaceuticals Inc (SHPH) via the Vested app. You can start investing in Shuttle Pharmaceuticals Inc (SHPH) with a minimum investment of $1.
You can invest in shares of Shuttle Pharmaceuticals Inc (SHPH) via Vested in three simple steps:
The 52-week high price of Shuttle Pharmaceuticals Inc (SHPH) is $4.94. The 52-week low price of Shuttle Pharmaceuticals Inc (SHPH) is $0.68.
The price-to-earnings (P/E) ratio of Shuttle Pharmaceuticals Inc (SHPH) is
The price-to-book (P/B) ratio of Shuttle Pharmaceuticals Inc (SHPH) is 4.16
The dividend yield of Shuttle Pharmaceuticals Inc (SHPH) is 0.00%
The market capitalization of Shuttle Pharmaceuticals Inc (SHPH) is $2.72M
The stock symbol (or ticker) of Shuttle Pharmaceuticals Inc is SHPH